Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Deferred Taxes (2022 - 2025)

Autolus Therapeutics (AUTL) has disclosed Deferred Taxes for 4 consecutive years, with -$13000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Deferred Taxes fell 107.74% year-over-year to -$13000.0, compared with a TTM value of -$1.0 million through Sep 2025, down 229.42%, and an annual FY2024 reading of $185000.0, down 81.24% over the prior year.
  • Deferred Taxes was -$13000.0 for Q3 2025 at Autolus Therapeutics, up from -$384000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $466000.0 in Q4 2023 and bottomed at -$487000.0 in Q1 2025.
  • Average Deferred Taxes over 4 years is -$2666.7, with a median of $37000.0 recorded in 2023.
  • The sharpest move saw Deferred Taxes soared 246.08% in 2023, then plummeted 418.92% in 2025.
  • Year by year, Deferred Taxes stood at -$319000.0 in 2022, then skyrocketed by 246.08% to $466000.0 in 2023, then tumbled by 130.26% to -$141000.0 in 2024, then soared by 90.78% to -$13000.0 in 2025.
  • Business Quant data shows Deferred Taxes for AUTL at -$13000.0 in Q3 2025, -$384000.0 in Q2 2025, and -$487000.0 in Q1 2025.